<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741686</url>
  </required_header>
  <id_info>
    <org_study_id>Konjac in Insulin Resistance</org_study_id>
    <nct_id>NCT03741686</nct_id>
  </id_info>
  <brief_title>Effect of Konjac-mannan in Individuals With Insulin-Resistance Syndrome</brief_title>
  <official_title>Beneficial Effects of Viscous Dietary Fiber From Konjac-Mannan in Subjects With the Insulin Resistance Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dicofarm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study whether a diet high in fiber from Konjac-mannan (KJM) has an effect on metabolic
      control in individuals with insulin resistance syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1991</start_date>
  <completion_date type="Actual">June 1999</completion_date>
  <primary_completion_date type="Actual">June 1992</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in total:HDL cholesterol</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change in fructosamine</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change in systolic blood pressure</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in total cholesterol</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in LDL cholesterol</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in HDL cholesterol</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in apolipoprotein A-1</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in apolipoprotain B</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in glucose</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in insulin</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in diastolic blood pressure</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in body weight</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in apoB:ApoA-1</measure>
    <time_frame>change from baseline after 3 weeks, relative to control</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Insulin Resistance Syndrome</condition>
  <arm_group>
    <arm_group_label>Konjac-mannan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>wheat bran fiber biscuits with NCEP Step II metabolically controlled diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>konjac glucomannan</intervention_name>
    <description>Konjac-mannan fiber-enriched biscuits (0.5 g/412KJ [100kcal] of glucommanan)</description>
    <arm_group_label>Konjac-mannan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>wheat bran</intervention_name>
    <description>Wheat bran (hard red wheat bran) fiber enriched biscuits</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Impaired glucose tolerant

          -  Clinical absent of CHD

          -  BMI less than 30 kg/m2

          -  Presence of full insulin resistance syndrome

          -  Reduced HDL cholesterol

          -  Elevated serum triglycerides

          -  Moderate hypertension

        Exclusion Criteria:

          -  Regular smoking

          -  Regular alcohol consumption

          -  Family history of premature coronary heart disease

          -  Hypothyroidism

          -  Renal, hepatic or gastrointestinal disease

          -  Taking medications for hyperglycemia

          -  Taking medications for hyperlipidemia

          -  Taking medications for hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin resistance syndrome</keyword>
  <keyword>fiber</keyword>
  <keyword>konjac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>(1-6)-alpha-glucomannan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

